Biotechnology
Compare Stocks
2 / 10Stock Comparison
LNAI vs TWST
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
LNAI vs TWST — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $8M | $3.65B |
| Revenue (TTM) | $0.00 | $409M |
| Net Income (TTM) | $-126M | $-81M |
| Gross Margin | — | 52.1% |
| Operating Margin | — | -33.9% |
| Total Debt | $10M | $137M |
| Cash & Equiv. | $93K | $183M |
Quick Verdict: LNAI vs TWST
Each card shows where this stock fits in a portfolio — not just who wins on paper.
LNAI carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.79
- Lower volatility, beta 0.79, current ratio 0.04x
- Beta 0.79, current ratio 0.04x
TWST is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 20.3%, EPS growth 63.9%, 3Y rev CAGR 22.8%
- 318.1% 10Y total return vs LNAI's -85.4%
- +78.6% vs LNAI's -85.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 21.7% revenue growth vs TWST's 20.3% | |
| Quality / Margins | -7.4% margin vs TWST's -19.8% | |
| Stability / Safety | Beta 0.79 vs TWST's 2.47 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +78.6% vs LNAI's -85.4% | |
| Efficiency (ROA) | -12.5% ROA vs LNAI's -18.8%, ROIC -26.9% vs -22.4% |
LNAI vs TWST — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
LNAI vs TWST — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
LNAI leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TWST and LNAI operate at a comparable scale, with $409M and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $0 | $409M |
| EBITDAEarnings before interest/tax | -$12M | -$115M |
| Net IncomeAfter-tax profit | -$126M | -$81M |
| Free Cash FlowCash after capex | -$6M | -$95M |
| Gross MarginGross profit ÷ Revenue | — | +52.1% |
| Operating MarginEBIT ÷ Revenue | — | -33.9% |
| Net MarginNet income ÷ Revenue | — | -19.8% |
| FCF MarginFCF ÷ Revenue | — | -23.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +19.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +80.8% | -7.6% |
Valuation Metrics
TWST leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $8M | $3.6B |
| Enterprise ValueMkt cap + debt − cash | $18M | $3.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.03x | -45.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 9.68x |
| Price / BookPrice ÷ Book value/share | — | 7.40x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
TWST leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
TWST delivers a -17.5% return on equity — every $100 of shareholder capital generates $-17 in annual profit, vs $-3 for LNAI. On the Piotroski fundamental quality scale (0–9), TWST scores 4/9 vs LNAI's 1/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -3.2% | -17.5% |
| ROA (TTM)Return on assets | -18.8% | -12.5% |
| ROICReturn on invested capital | -22.4% | -26.9% |
| ROCEReturn on capital employed | -33.2% | -24.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 0.29x |
| Net DebtTotal debt minus cash | $10M | -$46M |
| Cash & Equiv.Liquid assets | $92,700 | $183M |
| Total DebtShort + long-term debt | $10M | $137M |
| Interest CoverageEBIT ÷ Interest expense | -11.70x | — |
Total Returns (Dividends Reinvested)
TWST leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TWST five years ago would be worth $5,015 today (with dividends reinvested), compared to $1,461 for LNAI. Over the past 12 months, TWST leads with a +78.6% total return vs LNAI's -85.4%. The 3-year compound annual growth rate (CAGR) favors TWST at 63.5% vs LNAI's -47.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -65.7% | +80.7% |
| 1-Year ReturnPast 12 months | -85.4% | +78.6% |
| 3-Year ReturnCumulative with dividends | -85.4% | +336.9% |
| 5-Year ReturnCumulative with dividends | -85.4% | -49.9% |
| 10-Year ReturnCumulative with dividends | -85.4% | +318.1% |
| CAGR (3Y)Annualised 3-year return | -47.3% | +63.5% |
Risk & Volatility
Evenly matched — LNAI and TWST each lead in 1 of 2 comparable metrics.
Risk & Volatility
LNAI is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than TWST's 2.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TWST currently trades 88.7% from its 52-week high vs LNAI's 13.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 2.47x |
| 52-Week HighHighest price in past year | $2.45 | $66.00 |
| 52-Week LowLowest price in past year | $0.15 | $23.30 |
| % of 52W HighCurrent price vs 52-week peak | +13.6% | +88.7% |
| RSI (14)Momentum oscillator 0–100 | 43.6 | 57.0 |
| Avg Volume (50D)Average daily shares traded | 25.9M | 1.2M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $49.50 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% |
TWST leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). LNAI leads in 1 (Income & Cash Flow). 1 tied.
LNAI vs TWST: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is LNAI or TWST a better buy right now?
Analysts rate Twist Bioscience Corporation (TWST) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LNAI or TWST?
Over the past 5 years, Twist Bioscience Corporation (TWST) delivered a total return of -49.
9%, compared to -85. 4% for Lunai Bioworks Inc. (LNAI). Over 10 years, the gap is even starker: TWST returned +318. 1% versus LNAI's -85. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LNAI or TWST?
By beta (market sensitivity over 5 years), Lunai Bioworks Inc.
(LNAI) is the lower-risk stock at 0. 79β versus Twist Bioscience Corporation's 2. 47β — meaning TWST is approximately 213% more volatile than LNAI relative to the S&P 500.
04Which is growing faster — LNAI or TWST?
On earnings-per-share growth, the picture is similar: Twist Bioscience Corporation grew EPS 63.
9% year-over-year, compared to -18. 5% for Lunai Bioworks Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LNAI or TWST?
Lunai Bioworks Inc.
(LNAI) is the more profitable company, earning 0. 0% net margin versus -20. 6% for Twist Bioscience Corporation — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNAI leads at 0. 0% versus -36. 2% for TWST. At the gross margin level — before operating expenses — TWST leads at 50. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — LNAI or TWST?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is LNAI or TWST better for a retirement portfolio?
For long-horizon retirement investors, Lunai Bioworks Inc.
(LNAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 79)). Twist Bioscience Corporation (TWST) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LNAI: -85. 4%, TWST: +318. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between LNAI and TWST?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LNAI is a small-cap quality compounder stock; TWST is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.